References
- Amin M, Hersh CM. Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener. Dis. Manag. 13(1), 47–70 (2023).
- Hampel H, Hu Y, Hardy J et al. The amyloid-β pathway in Alzheimer’s disease: a plain language summary. Neurodegener. Dis. Manag. 13(3), 141–149 (2023).
- Montalban X, Wallace D, Genovese MC. A plain language summary of what clinical studies can tell us about the safety of evobrutinib – a potential treatment for multiple sclerosis. Neurodegener. Dis. Manag. 13(4), 207–213 (2023).
- Schmierer K, Wiendl H, Oreja-Guevara C et al. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. Neurodegener. Dis. Manag. 13(1), 15–21 (2023).
- Spelman T, Ozakbas S, Alroughani R et al. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. Neurodegener. Dis. Manag. 13(4), 215–221 (2023).
- Harrison EC, Earhart GM. The effect of auditory cues on gait variability in people with Parkinson’s disease and older adults: a systematic review. Neurodegener. Dis. Manag. 13(2), 113–128 (2023).
- Anwar MM, Fathi MH. Early approaches of YKL-40 as a biomarker and therapeutic target for Parkinson’s disease. Neurodegener. Dis. Manag. 13(2), 85–99 (2023).
- Vaughn CB, Kavak KS, Jakimovski D et al. Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon β-1a users. Neurodegener. Dis. Manag. 13(3), 151–159 (2023).
- Shih H-JS, Quinn L, Morgan-Jones P et al. Wearable activity monitors to support physical activity interventions in neurodegenerative disease: a feasibility study. Neurodegener. Dis. Manag. 13(3), 177–189 (2023).
- Montalban X, Wallace D, Genovese MC et al. A plain language summary of what clinical studies can tell us about the safety of evobrutinib – a potential treatment for multiple sclerosis. Neurodegener. Dis. Manag. 13(4), 207–213 (2023).
- Giovannoni G, Boyko A, Correale J et al. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: the CLASSIC-MS study. Neurodegener. Dis. Manag. 13(5), 261–268 (2023).
- Braeckman R, Oh C. A study of once-a-week donepezil transdermal system’s bioequivalence to oral donepezil in healthy volunteers: a plain language summary. Neurodegener. Dis. Manag. 13(6), 303–313 (2023).